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Abstract
Our objective was to evaluate the completeness of the United States National ALS Registry 
(Registry). We compared persons with ALS who were passively identified by the Registry with 
those actively identified in the State and Metropolitan Area ALS Surveillance project. Cases in the 
two projects were matched using a combination of identifiers, including, partial social security 
number, name, date of birth, and sex. The distributions of cases from the two projects that 
matched/did not match were compared and Chi-square tests conducted to determine statistical 
significance. There were 5883 ALS cases identified by the surveillance project. Of these, 1116 
died before the Registry started, leaving 4767 cases. We matched 2720 cases from the surveillance 
project to those in the Registry. The cases identified by the surveillance project that did not match 
cases in the Registry were more likely to be non-white, Hispanic, less than 65 years of age, and 
from western states. The methods used by the Registry to identify ALS cases, i.e. national 
administrative data and self-registration, worked well but missed cases. These findings suggest 
that developing strategies to identify and promote the Registry to those who were more likely to be 
missing, e.g. non-white and Hispanic, could be beneficial to improving the completeness of the 
Registry.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a rare progressive neurodegenerative disease that is 
diagnosed through a combination of signs and symptoms. A recent review of longstanding 
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European registries estimates incidence at 2.6 per 100,000 person years and prevalence rates 
of 7–9 per 100,000 persons (1). Some studies suggest that ALS rates are higher among non-
Hispanic Caucasians (whites) in western countries compared with those of African, Asian, 
and Hispanic descent (minorities) (2–4). There are limited data regarding the population-
based epidemiology of ALS in the United States (US) with most studies having been 
conducted in limited geographic areas (5–7). Recent data from the National ALS Registry 
estimated prevalence of ALS in the United States at 5.0 per 100,000 population in 2013 (8).
In October 2010, the Agency for Toxic Substances and Disease Registry (ATSDR) launched 
the National Amyotrophic Lateral Sclerosis (ALS) Registry (Registry) to implement Public 
Law No: 110-373 which signed into law a bill to amend the Public Health Service Act to 
provide for the establishment of an Amyotrophic Lateral Sclerosis Registry. Because of the 
challenges experienced by ATSDR and other researchers trying to obtain information 
directly from medical care providers, the National ALS Registry uses nontraditional 
methods to identify persons with ALS including using administrative data from the Centers 
for Medicaid and Medicare Services (CMS), the Veterans Health Administration (VHA), 
and the Veterans Benefits Administration (VBA), and a self-registration component (9,10). 
In order to evaluate the completeness of the National ALS Registry, ATSDR conducted a 
separate ALS surveillance project using active case-finding methods in three states (Florida, 
New Jersey, and Texas) and eight metropolitan areas (Atlanta, Baltimore, Chicago, Detroit, 
Las Vegas, Los Angeles, Philadelphia, and San Francisco) (11) and calculated the 
concordance between the two sources. A bill to amend the Public Health Service Act to 
provide for the establishment of an Amyotrophic Lateral Sclerosis Registry, S. 1382: ALS 
Registry Act, was signed into law on October 10, 2008 by President George W. Bush and 
became Public Law No: 110-373. The purpose of the Registry as described in the bill, is to 
(1) better describe the incidence and prevalence of ALS in the United States; (2) examine 
appropriate factors, such as environmental and occupational, that might be associated with 
the disease; (3) better outline key demographic factors (such as age, race or ethnicity, 
gender, and family history of individuals who are diagnosed with the disease) associated 
with the disease; and (4) better examine the connection between ALS and other motor 
neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases 
progress to ALS (12). The Registry collects personal health information that may provide a 
basis for further scientific studies of potential risks for developing ALS.
ATSDR developed and tested case-finding methodology for the National ALS Registry that 
identified ALS cases using administrative data from CMS, VHA, and VBA. The Registry 
pilot study developed an algorithm using variables from the administrative data that 
identified true cases of ALS. The best algorithm had a sensitivity of 87% and a specificity of 
85%. The pilot study sites identified <1–22% of the cases in only the clinical databases and 
therefore missed by administrative data alone. The study results showed that administrative 
data could be used to create an ALS surveillance system although it would be necessary to 
identify other sources of data or methods to capture those ALS cases not covered by the 
administrative databases (13). A self-registration component was initiated because of 
previous experience trying to obtain information directly from medical care providers. In 
October 2010, ATSDR launched a web-portal where persons with ALS could enroll in the 
National ALS Registry. To enter the National ALS Registry through its web portal, patients 
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must answer a series of validation (screening) questions. These validation questions were 
obtained from the Veterans Administration’s ALS Registry (which is no longer enrolling 
persons with ALS) and were found to be effective; 93.4% of those who passed the screening 
questions were determined by a neurologist to have ALS/motor neuron disease (14). This 
two-pronged approach tries to identify all cases of ALS within the United States (8–10).
Traditionally in the United States, surveillance systems have relied on physicians and other 
health care providers to report notifiable health information to state or local health 
departments and when appropriate this information is reported to federal health authorities. 
In the United States, the designation of a “reportable” health condition is conferred by the 
Council of State and Territorial Epidemiologists (CSTE) and this designation is usually 
reserved for infectious diseases. Because ALS is not an infectious disease, it is not 
considered a “reportable/notifiable” disease. In this assessment, we evaluated the 
completeness of the Registry by comparing ALS cases identified in the selected state and 
metropolitan areas which used traditional case ascertainment methods to those ALS cases 
identified by the Registry which used non-traditional surveillance case ascertainment 
methods.
Materials and methods
We compared the cases of ALS identified by the two different case ascertainment methods, 
the National ALS Registry and the state and metropolitan surveillance project. In brief, the 
National ALS Registry uses a two-pronged approach, i.e. administrative databases and self-
registration. The state and metropolitan area surveillance projects used active case 
ascertainment, i.e. physician reporting, medical records abstraction, and death certificates. In 
the state and metropolitan area surveillance project, areas were selected to over-represent 
racial and ethnic minorities so that the number of cases in these groups would be sufficient 
to estimate prevalence by race and ethnicity. A detailed description of this methodology can 
be found in the paper by Wagner et al. (11).
The state and metropolitan surveillance project collected prevalent cases of ALS for January 
1, 2009 through December 31, 2011 while the National ALS Registry began to identify 
cases on October 19, 2010. Therefore, we submitted the cases identified by the state and 
metropolitan surveillance project to the National Death Index to obtain date of death when 
available. All cases identified in the state and metropolitan area surveillance project who 
died before the start of the Registry, October 19, 2010, were removed from further analysis. 
This adjustment made the time-period for both projects’ case ascertainments the same, 
October 19, 2010 through December 31, 2011.
Because of state privacy and human subjects protection regulations, ALS cases identified in 
the state and metropolitan projects could not be added to the National ALS Registry and 
could only be used for comparison purposes. Cases in the two projects were matched using a 
combination of information identifying including partial SSN, name, date of birth, and sex. 
The distribution of cases from the state and metropolitan surveillance system that matched 
or did not match the National ALS Registry were compared. Chi-square tests were 
conducted to determine whether there was a statistically significant difference in the 
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characteristics of cases identified in the state and metropolitan area surveillance project 
being/or not being identified by the Registry. An alpha level of p = 0.05 was used to 
determine statistical significance.
Multivariable regression analyses were used to examine whether cases matched between the 
two data sources differed, as well as to examine interaction between case characteristics. 
When examining interactions, we included the main effect variables along with the 
corresponding interaction terms. The interaction terms examined included: age group and 
Medicare, race and state, age group and El Escorial criteria, and race and El Escorial criteria. 
Stepwise model selection method was applied with an inclusion criterion of p ≤ 0.10. All 
data analysis was performed using SAS© (15).
Results
The state and metropolitan surveillance project identified 5883 cases of ALS. Of these, 1116 
died before the National ALS Registry started, leaving us 4767 cases. Of the 4767 cases 
identified by the state and metropolitan surveillance project and alive during the eligibility 
period (October 19, 2010 through December 31, 2011), 2720 (57%) matched a case 
identified by the National ALS Registry. The cases identified by the state and metropolitan 
area surveillance project that did not match cases in the Registry were more likely to be non-
white, Hispanic, less than 65 years of age, and from western states (Table 1). In addition to 
demographic differences between those identified by the state and metropolitan surveillance 
project who matched and those who did not match cases identified by the Registry, there 
were significant differences in the stage of ALS at the time of the report and the types of 
insurance used, i.e. those who were diagnosed with possible or unclassified ALS and those 
who did not use Medicare were less likely to be identified by the National ALS Registry 
(Table 2).
The best model for the multiple logistic regression analysis showed an ALS case identified 
in the state and metropolitan surveillance projects was less likely to be in the National ALS 
Registry if nonwhite, Hispanic, living in the western part of the US, and not having 
Medicare for insurance (Table 3). According to the stepwise methods, no interactions were 
significant (data not shown).
Discussion
There have been a number of smaller efforts to establish surveillance systems for 
neurodegenerative diseases in the US such as ALS, Parkinson’s disease, and Alzheimer’s 
disease/dementia (7,16–19), the National ALS Registry however, is the first attempt in the 
US to create a national surveillance system for any neurodegenerative disease. These smaller 
efforts used a variety of case ascertainment methods including physician reporting, medical 
claims data, prescription data for disease specific medications, advocacy group reporting, 
and self-reporting making them difficult to compare. ALS registries in Europe have been 
operating for about two decades and provide insights in how to operate a successful registry 
along with limitations (1,20). However, because of the health care delivery system along 
with the ethnic/racial diversity and population size of the US (more than 300 million 
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compared with the approximately 26 million in the six population registries used to estimate 
ALS incidence in Europe) (21), it is not possible to create a national registry in the US using 
the same methodology as used in Europe. What is clear is that it is important to obtain 
information from multiple sources such as medical claims data, prescription data, physician 
reporting, when feasible, and self-identification in order to have the most complete 
ascertainment possible.
Therefore, because of the fractured health care system in the United States, the National 
ALS Registry has used a unique two-pronged approach to identify persons with ALS, i.e. 
cases identified via an algorithm in federal administrative datasets and self-registration 
(8,10,13). Although the Registry identified 13,282 for a revised prevalence of 4.3 in 2011 
(8), it was anticipated that individuals with ALS could be missing. The comparison of a 
cohort of ALS cases actively collected from neurologists in a geographically and racially/
ethnically diverse population allowed for the identification of subgroups of the population 
that are more likely to be missing from the Registry. This comparison showed that a person 
with ALS was more likely to be missing from the Registry if they were non-white, Hispanic, 
living in the western part of the United States, and were not using Medicare for insurance. 
This could be because those who are non-white or Hispanic are less likely to be seen in ALS 
specialty clinics and therefore less likely to learn about the Registry. It could also be because 
they have less access to computers which are needed for self-registration. Racial difference 
could also explain the difference seen by region of the country as the West Census Region is 
47% minority according to the 2010 census (22). Although those with ALS are eligible for 
Medicare once receiving Social Security Disability Insurance (SSDI) (23), this group may 
be less likely to be eligible for SSDI because of the jobs held, length of employment, or 
knowledge about this benefit. In addition, those with a less definitive diagnosis of ALS 
based on the El Escorial criteria reported in the state and metropolitan surveillance project 
were also more likely to be missing. This could be because those being told that they 
“possibly have ALS” are less likely to seek benefits for ALS or self-register even though 
studies have shown that those given a diagnosis of suspected or possible ALS El Escorial 
category do have ALS (24). An El Escorial criteria category is not available in the Registry 
because it is not available in administrative claims data and not something that is self-
reported in the registration portal.
Age was not significant in the logistic regression analysis; however, those identified in the 
state and metropolitan surveillance project who were not in the Registry were more likely to 
be less than 65 years of age. Like race, this could be related to those less than 65 years of 
age only being eligible for Medicare after receiving SSDI. This could delay identifying them 
in administrative data and making their identification more reliant on self-enrollment in the 
Registry.
Although the incidence rate of ALS among nonwhites is lower than that for whites (2,3), this 
should not impact who is identified by the Registry, e.g. the percentage of people identified 
by race and ethnicity should be the same. The National ALS Registry has partnered with 
national and regional ALS patient advocacy groups such as the ALS Association (ALSA), 
Muscular Dystrophy Association (MDA), and the Les Turner ALS Foundation to educate 
and increase awareness. These groups directly work with ALS patients and their caregivers 
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providing assistance and coordinating care. In general, the patient population served by these 
groups tends to be white with a mixture of chapter and clinic locations where a larger 
percentage of minority groups are represented, such as Los Angeles, San Francisco, Atlanta, 
Chicago, and Miami. ATSDR will work with these groups to target outreach to minority 
populations. However, more targeted outreach will likely be needed because minority 
populations tend to be under-represented in support groups (25,26).
In 2017, in order to reach more Hispanics with ALS, ATSDR will launch a site in Spanish 
where individuals can learn more about ALS, register, and take risk factor surveys. Once 
launched, a Spanish public service announcement will be disseminated via social media such 
as Facebook and Twitter and through our partner groups to educate individuals about ALS 
and facets of the Registry. In addition, ATSDR is exploring opportunities to work with 
national Spanish groups such as the National Hispanic Medical Association, National 
Council of La Raza, and others.
To better reach African Americans with ALS, the Registry plans to reach out to 
organizations such as the National Medical Association, large churches located in 
metropolitan areas serving the African American community, as well as the National 
Association for the Advancement of Colored People. This targeted approach should allow 
the Registry to reach underserved and under-represented populations.
The Registry is also exploring ways to work with neurologists not practicing at major 
academic facilities or ALS specialty clinics to make them aware of the Registry so that they 
can inform their patients. However, this is particularly challenging because this group of 
neurologists changes frequently due to relocations, retirements, and new graduates entering 
the specialty. In addition, this group of neurologists may only occasionally see an ALS 
patient (11). It will be important to develop messaging specific for this group that can be 
used on a regular basis so that the neurologists remembers the Registry and can provide 
materials to an ALS patient when one is seen.
Conclusions
Although the comparison of a cohort of ALS cases actively collected from neurologists in a 
geographically and racially/ethnically diverse population compared with those identified by 
the National ALS Registry identified subgroups of the population that are more likely to be 
missing from the Registry, the Registry has been able to increase the number of cases 
detected since the first report (6) covering October 19, 2010 through December 31, 2011. In 
addition, the Registry can use this valuable information to target under-represented groups 
and has developed a plan for outreach to these populations. The National ALS Registry is 
committed to increasing racial and ethnic minority enrollment on a local and national scale 
in order to have more complete epidemiological data on ALS in the United States.
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